Increasing susceptibility of nitric oxide-mediated inhibitory platelet signaling during storage of apheresis-derived platelet concentrates

Transfusion

Volumn 54, Issue 7, 2014, Pages 1782-1789

  Kobsar, Anna ^a   Klinker, Erdwine ^a   Kuhn, Sabine ^a   Koessler, Angela ^a   Yilmaz, Pinar ^a   Boeck, Markus ^a   Koessler, Juergen ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE; DIETHYLAMINE DIAZENIUM DIOLATE; FIBRINOGEN; NITRIC OXIDE DONOR; SERINE; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

APHERESIS; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; NORMAL HUMAN; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE PRESERVATION; VENOUS BLOOD;

ADULT; BLOOD PLATELETS; BLOOD PRESERVATION; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELETPHERESIS; TIME FACTORS; YOUNG ADULT;

EID: 84904468080     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12584     Document Type: Article

References (23)

1. Cauwenberghs S, van Pampus E, Curvers J, et al. Hemostatic and signaling functions of transfused platelets. Transfus Med Rev 2007; 21: 287-294.
2. Lozano ML, Rivera J, Gonzalez-Conejero R, et al. Loss of high-affinity thrombin receptors during platelet concentrate storage impairs the reactivity of platelets to thrombin. Transfusion 1997; 37: 368-375.
3. Schlagenhauf A, Kozma N, Leschnik B, et al. Thrombin receptor levels in platelet concentrates during storage and their impact on platelet functionality. Transfusion 2012; 52: 1253-1259.
4. Perez-Pujol S, Aras O, Lozano M, et al. Stored platelets contain residual amounts of tissue factor: evidence from studies on platelet concentrates stored for prolonged periods. Transfusion 2005; 45: 572-579.
5. Rudderow D, Soslau G,. Permanent lesions of stored platelets correlate to pH and cell count while reversible lesions do not. Proc Soc Exp Biol Med 1998; 217: 219-227.
6. Shapira S, Friedman Z, Shapiro H, et al. The effect of storage on the expression of platelet membrane phosphatidylserine and the subsequent impacton the coagulant function of stored platelets. Transfusion 2000; 40: 1257-1263.
7. Albanyan AM, Murphy MF, Harrison P,. Evaluation of the Impact-R for monitoring the platelet storage lesion. Platelets 2009; 20: 1-6.
8. Schwarz UR, Walter U, Eigenthaler M,. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001; 62: 1153-1161.
9. Butt E, Abel K, Krieger M, et al. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 1994; 269: 14509-14517.
10. Schwarz UR, Geiger J, Walter U, et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets-definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
11. Smolenski A, Bachmann C, Reinhard K, et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem 1998; 273: 20029-20035.
12. Aszodi A, Pfeifer A, Ahmad M, et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999; 18: 37-48.
13. Massberg S, Gruner S, Konrad I, et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood 2004; 103: 136-142.
14. Eigenthaler M, Nolte C, Halbrugge M, et al. Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 1992; 205: 471-481.
15. Kobsar A, Putz E, Yilmaz P, et al. Decreasing phosphodiesterase 5A activity contributes to platelet cGMP accumulation during storage of apheresis-derived platelet concentrates. Transfusion in press 2014. doi: 10.1111/trf.12360.
16. Sogo N, Magid KS, Shaw CA, et al. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun 2000; 279: 412-419.
17. Crane MS, Rossi AG, Megson IL,. A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. Br J Pharmacol 2005; 144: 849-859.
18. Friebe A, Koesling D,. The function of NO-sensitive guanylyl cyclase: what we can learn from genetic mouse models. Nitric Oxide 2009; 21: 149-156.
19. Ferrero R, Rodriguez-Pascual F, Miras-Portugal MT, et al. Comparative effects of several nitric oxide donors on intracellular cyclic GMP levels in bovine chromaffin cells: correlation with nitric oxide production. Br J Pharmacol 1999; 127: 779-787.
20. Schubert P, Culibrk B, Coupland D, et al. Riboflavin and ultraviolet light treatment potentiates vasodilator-stimulated phosphoprotein Ser-239 phosphorylation in platelet concentrates during storage. Transfusion 2012; 52: 397-408.
21. Gudmundsdottir IJ, McRobbie SJ, Robinson SD, et al. Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. Biochem Biophys Res Commun 2005; 337: 382-385.
22. Roger S, Badier-Commander C, Paysant J, et al. The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide. Br J Pharmacol 2010; 161: 1044-1058.
23. Chlopicki S, Lomnicka M, Fedorowicz A, et al. Inhibition of platelet aggregation by carbon monoxide-releasing molecules (CO-RMs): comparison with NO donors. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 641-650.